The global interventional cardiology devices market is projected to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031 at a 6.4% CAGR (compound annual growth rate), according to MarketsandMarkets™. Within the broader market, the global intravascular lithotripsy (IVL) market was valued at USD 1.01 billion in 2025 and is projected to reach USD 4.19 billion by 2035 at a 15.3% CAGR, according to SNS Insider. Growth is being supported by the rising prevalence of cardiovascular disease, population aging, diabetes, obesity and hypertension, as well as the shift from open-heart surgery toward minimally invasive, catheter-based procedures. IVL uses catheter-generated pressure waves to fracture vascular calcium deposits while limiting damage to surrounding soft tissue, helping prepare heavily calcified coronary and peripheral lesions for angioplasty and stenting. In the broader market, drug-eluting stents are identified as the largest angioplasty-stent segment in one MarketsandMarkets classification and the fastest-growing segment in another, angiography catheters hold the largest catheter share, and IVUS/OCT catheters are expanding fastest. In the IVL market, catheters and balloons held about 56.0% of 2025 revenue, coronary IVL held 58.0%, coronary artery disease accounted for roughly 52.0% and hospitals about 66.0%. North America led both markets, while Asia Pacific was identified as the fastest-growing IVL region. Opportunities include outpatient care, catheterization-lab expansion in emerging economies, peripheral and below-the-knee IVL procedures, and AI-enabled digital cath labs. Procedure-related complications remain a restraint. In 2025, Boston Scientific, Medtronic, Abbott, Edwards Lifesciences and Terumo together accounted for approximately 64–68% of the broader market.